The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Jun 19, 2026
Compounding Gems Aravalli Fund's core investment thesis focuses on patient capital allocation toward high-quality Indian businesses that offer sustainable compounding growth over a multi-year horizon. The global economic backdrop remains complex, marked by persistent geopolitical tensions, uneven growth trajectories, and tighter financial conditions with prolonged elevated interest rates. Within this landscape, Indian equities lagged other global and emerging peers in 2025 due to capital outflows toward stronger near-term narratives in other markets. However, the fund manager anticipates a positive shift in 2026 as domestic valuations have normalized and the corporate earnings downgrade cycle appears to be concluding. To mitigate risk and capitalize on better relative value, the fund has strategically increased its exposure to larger-cap enterprises over more volatile small- and mid-cap segments. Key risks include US tariffs, trade protectionism, and labor supply shocks, which may disrupt India's otherwise resilient domestic-led growth trajectory.
Patient long-term compounding in high-quality Indian equities, particularly transitioning to larger-cap companies with robust fundamentals, is the optimal path to navigate global macroeconomic shifts.
The manager anticipates a recovery for Indian equities in 2026 driven by more reasonable valuations and an end to the earnings downgrade cycle. While acknowledging near-term volatility and global headwinds like tariffs, the long-term structural path for India remains compelling, supported by domestic demand and infrastructure development.
Neutral / Balanced
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Compounding Gems Aravalli Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.